Document:

EX-10.3

 Exhibit 10.3 

STOCKHOLDERS AGREEMENT 

THIS STOCKHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of March 30, 2021, by and among Alignment
Healthcare, Inc., a Delaware corporation (the “Company”), General Atlantic (ALN HLTH), LP, a Delaware limited partnership (together with its affiliated investment entities, the “GA Stockholder”), and Warburg Pincus
Private Equity XII, L.P., a Delaware limited partnership, WP XII Partners, L.P., a Delaware limited partnership, Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership, Warburg Pincus XII
Partners, L.P., a Delaware limited partnership, Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership, and Warburg Pincus Private Equity XII-E, L.P.,
a Delaware limited partnership (collectively, the “Warburg Stockholder” and, together with the GA Stockholder, the “Lead Stockholders”). 

RECITALS 
 WHEREAS, as of
the date hereof, the Lead Stockholders collectively hold a majority of the outstanding capital stock of the Company; 
 WHEREAS, in
connection with, and effective upon, the date of completion of the initial public offering of the Company (the “Effective Date”), the Company and the Lead Stockholders wish to set forth certain understandings between such parties,
including with respect to certain governance matters. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained
herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Lead Stockholders agree as follows: 

AGREEMENT 

1.    Defined Terms. In addition to the terms defined elsewhere herein, the following terms have the following meaning when used
herein with initial capital letters: 
 “Affiliate” of any Person shall mean any other Person controlled by, controlling or
under common control with such first Person; where “control” (including, with its correlative meanings, “controlling,” “controlled by” and “under common control with”) means possession,
directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities, by contract or otherwise). 

“Beneficially Own” shall mean that a specified person has or shares the right, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise, to vote shares of capital stock of the Company. 
 “Board” means the
board of directors of the Company. 
 “Common Stock” means common stock of the Company, par value $0.001 per share. 

“Director” means any member of the Board. 

 “Indebtedness” means (a) all indebtedness of the Company and
any of its Subsidiaries for borrowed money, (b) all obligations of the Company and any of its Subsidiaries evidenced by bonds, debentures, notes, loan agreements or other similar instruments, (c) the amount of all drafts drawn under any
and all letters of credit issued for the account of the Company or any of its Subsidiaries (but only to the extent of any unreimbursed drawings under any letter of credit), (d) all Indebtedness of any other Person secured by any Lien on
any property owned by the Company or any of its Subsidiaries, whether or not such Indebtedness has been assumed by the Company or any of its Subsidiaries (but only to the extent it becomes
non-contingent), (e) all obligations of the Company and any of its Subsidiaries to pay the deferred purchase price of property or services (including any earnout obligation), except trade accounts payable
arising and paid in the ordinary course of business, (f) the capitalized amount of all capital leases of the Company and any of its Subsidiaries, (g) any liability of the Company or any of its Subsidiaries under any interest rate, currency
or commodity swap agreement, cap agreement or collar agreement, and any other agreement or arrangement designed to protect the Company and any of its Subsidiaries against fluctuations in interest rates, currency exchange rates or commodity prices,
(h) all guarantees with respect to any Indebtedness of any other Person of the type described in clauses (a) through (g) of this definition. 

“Lien” means any encumbrance, restriction, claim, mortgage, pledge, charge, assignment, hypothecation, security interest,
title retention, banker’s lien, privilege or priority of any kind having the effect of security. 
 “Person” means any
individual, corporation, limited liability company, partnership, trust, joint stock company, business trust, unincorporated association, joint venture, governmental authority or other entity or organization, including a government or any subdivision
or agency thereof. 
 “Subsidiary” means with respect to any Person, any corporation, limited liability company,
partnership, association, trust or other form of legal entity, of which (a) such first Person directly or indirectly owns or controls at least a majority of the securities or other interests having by their terms voting power to elect a
majority of the board of directors or others performing similar functions, or (b) such first Person is a general partner or managing member (excluding partnerships in which such Person or any Subsidiary thereof does not have a majority of the
voting interests in such partnership). 
  

	2.	 Board of Directors. 

(a)    Subject to the other provisions of this Section 2, as of the Effective Date, the number of
Directors constituting the full Board shall initially be fixed at nine (9), who shall be divided into three (3) classes of Directors in accordance with the terms of the Company’s Certificate of Incorporation. As of the Effective Date, the
nine (9) directors shall be divided into three (3) classes as follows: 
 (i)    the Class I Directors
shall include Mark McClellan, Robbert Vorhoff and Thomas Carella; 

  
 2 

 (ii)    the Class II Directors shall include David Hodgson,
Jacqueline Kosecoff and Jeff Margolis; and 
 (iii)    the Class III Directors shall include John Kao, Joseph
Konowiecki and Margaret McCarthy. 
 (b)    For the avoidance of doubt, Section 2(a) is
applicable solely to the initial composition of the Board, except that, subject to the Company’s Certificate of Incorporation, a Director shall remain a member of the class of Directors to which he or she was assigned in accordance with
Section 2(a). 
 (c)    From the Effective Date, the GA Stockholder shall have the right, but
not the obligation, to nominate to the Board a number of designees (such persons, the “Nominees”) equal to at least: (i) four (4) Directors, so long as the GA Stockholder Beneficially Owns shares of Common Stock representing
over 35% of the Common Stock then outstanding, (ii) three (3) Directors, so long as the GA Stockholder Beneficially Owns shares of Common Stock representing over 25% but less than or equal to 35% of the Common Stock then outstanding,
(iii) two (2) Directors so long as the GA Stockholder Beneficially Owns shares of Common Stock representing over 15% but less than or equal to 25% of the Common Stock then outstanding and (iv) one (1) Director so long as the GA Stockholder
Beneficially Owns shares of Common Stock representing at least 5% but less than or equal to 15% of the Common Stock then outstanding. The initial Nominees of the GA Stockholder shall be Robbert Vorhoff (as a Class I Director) and David Hodgson
(as a Class II Director). At the GA Stockholder’s request, each class of Directors shall include, to the extent practicable, at least one Nominee designated by the GA Stockholder. 

(d)    From the Effective Date, the Warburg Stockholder shall have the right, but not the obligation, to nominate to the
Board one (1) Director so long as the Warburg Stockholder Beneficially Owns shares of Common Stock representing at least 5% of the Common Stock then outstanding. The initial Nominee of the Warburg Stockholder shall be Thomas Carella (as a
Class I Director). 
 (e)    In the event that either the GA Stockholder or the Warburg Stockholder has nominated
less than the total number of designees that such Lead Stockholder shall be entitled to nominate pursuant to Section 2(c) and Section 2(d), as applicable, such Lead Stockholder shall have the
right, at any time, to nominate such additional designees to which it is entitled, in which case, the Company and the Directors shall take all necessary corporation action, to the fullest extent permitted by applicable law (including with respect to
fiduciary duties under Delaware law), to (x) enable such Lead Stockholder to nominate and effect the election or appointment of such additional individuals, whether by increasing the size of the Board, or otherwise and (y) to designate
such additional individuals nominated by such Lead Stockholder to fill such newly created vacancies or to fill any other existing vacancies. 

(f)    The Company shall pay all reasonable
out-of-pocket expenses incurred by any Nominee in connection with the performance of his or her duties as a Director and in connection with his or her attendance at any
meeting of the Board. 

  
 3 

 (g)    No reduction in the number of shares of Common Stock that each
Lead Stockholder Beneficially Owns shall shorten the term of any incumbent Director. 
 (h)    In the event that any
Nominee shall cease to serve for any reason during a term, the Lead Stockholder that nominated such Nominee shall be entitled to designate such person’s successor in accordance with this Agreement (regardless of each Lead Stockholder’s
Beneficial Ownership of Common Stock at the time of such vacancy) and the Board shall promptly fill the vacancy with such successor nominee; it being understood that any such designee shall serve the remainder of the term of the Director whom such
designee replaces. 
 (i)    If a Nominee is not appointed or elected to the Board because of such person’s death,
disability, disqualification, withdrawal as a Nominee or for another reason is unavailable or unable to serve on the Board, the applicable Lead Stockholder shall be entitled to designate promptly another Nominee and the Director position for which
the original Nominee was nominated shall not be filled pending such designation. 
 (j)    At such times as the Company
is required by applicable law or stock exchange listing standards to have a majority of the Board comprised of “independent directors” (subject in each case to any applicable phase-in periods), the
Nominees shall include a number of persons that qualify as “independent directors” under applicable law and stock exchange listing standards such that, together with any other “independent directors” then serving on the Board
that are not Nominees, the Board is comprised of a majority of “independent directors”; provided, that at any time that a Lead Stockholder shall have any nomination rights under this Section 2, each such
Lead Stockholder shall be entitled to nominate at least one (1) Nominee who does not qualify as an “independent director”. 
  

	3.	 Company and Lead Stockholder Obligations. 

(a)    The Company agrees that, prior to the date that each Lead Stockholder ceases to Beneficially Own shares of Common
Stock representing at least 5% of the Common Stock then outstanding, (i) each Nominee is included in the Board’s slate of nominees to the stockholders (the “Board’s Slate”) for each election of Directors; and
(ii) each Nominee is included in the proxy statement prepared by management of the Company in connection with soliciting proxies for every meeting of the stockholders of the Company called with respect to the election of Directors (each, a
“Director Election Proxy Statement”), and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company or the Board with respect to the election of members of
the Board. Each Lead Stockholder will promptly report to the Company after such Lead Stockholder ceases to Beneficially Own shares of Common Stock representing at least 5% of the Common Stock then outstanding, such that the Company is informed of
when this obligation terminates; provided, that such obligation of such Lead Stockholder to notify the Company shall be deemed satisfied if such Lead Stockholder makes a filing under Section 16 of the Securities Exchange Act of 1934
reflecting such change in the Common Stock Beneficially Owned by such Lead Stockholder. The calculation of the number of Nominees that each Lead Stockholder is entitled to nominate to the Board’s Slate for any election of Directors shall be
based on the percentage of the Common Stock then outstanding Beneficially Owned by each Lead Stockholder (“Lead Stockholder Voting Control”) immediately prior to the mailing to stockholders of the Director Election Proxy Statement
relating to such election (or, if 

  
 4 

 
earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission). Unless a Lead Stockholder notifies the Company otherwise prior to the
mailing to stockholders of the Director Election Proxy Statement relating to an election of Directors, the Nominees for such election shall be presumed to be the same Nominees currently serving on the Board, and no further action shall be required
of any Lead Stockholder for the Board to include such Nominees on the Board’s Slate; provided, that, in the event a Lead Stockholder is no longer entitled to nominate the full number of Nominees then serving on the Board, such Lead
Stockholder shall provide advance written notice to the Company of which currently serving Nominee(s) shall be excluded from the Board Slate, and of any other changes to the list of Nominees. If a Lead Stockholder fails to provide such notice prior
to the mailing to stockholders of the Director Election Proxy Statement relating to such election (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission), a majority of the
independent directors then serving on the Board shall determine which of the Nominees of such Lead Stockholder then serving on the Board will be included in the Board’s Slate. 

(b)    At any time that a Lead Stockholder shall have any nomination rights under Section 2, the
Company shall not take any action, including making or recommending any amendment to Company’s Certificate of Incorporation or Bylaws (each as may be further amended, supplemented or waived in accordance with its terms) that could reasonably be
expected to adversely affect a Lead Stockholder’s rights under this Agreement, in each case without the prior written consent of the adversely affected Lead Stockholder. 
  

	4.	 Committees. 

(a)    From and after the Effective Date until such time as any Lead Stockholder ceases to Beneficially Own Common Stock
representing at least 10% of the Common Stock then outstanding, such Lead Stockholder shall have the right to designate one member of each committee of the Board; provided, that any such designee shall be a Director and shall be eligible to
serve on the applicable committee under applicable law or stock exchange listing standards, including any applicable independence requirements (subject in each case to any applicable exceptions, including those for newly public companies and any
applicable phase-in periods). Any additional committee members shall be determined by the Board. Nominees designated to serve on a Board committee shall have the right to remain on such committee until the
next election of Directors, regardless of the level of Lead Stockholder Voting Control following such designation. Unless a Lead Stockholder notifies the Company otherwise prior to the time the Board takes action to change the composition of a Board
committee, and to the extent the applicable Lead Stockholder has the requisite Lead Stockholder Voting Control for such Lead Stockholder to nominate a Board committee member at the time the Board takes action to change the composition of any such
Board committee, any Nominee currently designated by the applicable Lead Stockholder to serve on a committee shall be presumed to be re-designated for such committee. 

(b)    From and after the Effective Date until such time as the GA Stockholder ceases to Beneficially Own Common Stock
representing at least 15% of the Common Stock then outstanding, the Company shall take all necessary action to cause the chairperson of the Compensation Committee of the Board to be a person selected by the GA Stockholder from among the Directors
then in office from time to time. 

  
 5 

 5.    Major Actions. In addition to any voting requirements contained in the
Certificate of Incorporation or the Bylaws (or similar governing documents) of the Company or any of its Subsidiaries, the following actions shall not be taken by the Company or any of its Subsidiaries, directly or indirectly (whether by merger,
consolidation or otherwise), including any proposal by the Board to put to the vote of the stockholders of the Company with respect thereto, without the prior written consent of the GA Stockholder for so long as the GA Stockholder Beneficially Owns
shares of Common Stock representing at least 25% of the Common Stock then outstanding: 
 (a)    any acquisition or
disposition where aggregate consideration is greater than $200,000,000 in a single transaction or series of related transactions; 

(b)    any transaction in which any Person or group acquires more than 50% of the then outstanding capital stock of the
Company or the power to elect a majority of the members of the Board; 
 (c)    any incurrence or refinancing of
Indebtedness of the Company and its Subsidiaries to the extent such incurrence or refinancing would result in the Company and its Subsidiaries having Indebtedness in excess of $250,000,000 in the aggregate; 

(d)    hiring or termination of the chief executive officer of the Company; 

(e)    any increase or decrease in the size of the Board; or 

(f)    any reorganization, recapitalization, voluntary bankruptcy, liquidation, dissolution or winding-up. 
 6.    Confidential Information. The Company recognizes that Nominees
(a) will from time to time receive non-public information concerning the Company, and (b) may share such information with other individuals associated with the Lead Stockholder that designated such
Nominee. The Company hereby irrevocably consents to such sharing, subject to the terms of this Section 6. Each Lead Stockholder agrees that it will keep confidential and not disclose or divulge to any third party, or use for any purpose, other
than to monitor its investment in the Company and its Subsidiaries, any confidential information regarding the Company it receives from the Company or a Nominee, unless such information (x) is known or becomes known to the public in general,
(y) is or has been independently developed or conceived by such Lead Stockholder without use of the Company’s confidential information or (z) is or has been made known or disclosed to such Lead Stockholder by a third party without a
breach of any obligation of confidentiality such third party may have; provided, however, that a Lead Stockholder may disclose confidential information (i) to its Affiliates (other than portfolio companies), (ii) to each of its
and its Affiliates’ (other than portfolio companies) attorneys, accountants, consultants, advisors and other professionals to the extent necessary to obtain their services in connection with evaluating the information, or (iii) as may be
required by law or legal, judicial or regulatory process or requested by any regulatory or self-regulatory authority or examiner, provided that such Lead Stockholder takes reasonable steps to minimize the extent of any required disclosure described
in this clause (iii); provided, further, that each Lead Stockholder shall be responsible for compliance with this Section 6 by its Affiliates and advisors described in the foregoing clauses (i) and (ii). 

  
 6 

	7.	 Indemnification. 

(a)    The Company agrees to indemnify and hold harmless each Lead Stockholder, its respective directors, officers,
partners, members, managers, Affiliates and controlling persons (each, an “Stockholder Indemnitee”) from and against any and all liability, including, without limitation, all obligations, costs, fines, claims, actions, injuries,
demands, suits, judgments, proceedings, investigations, arbitrations (including stockholder claims, actions, injuries, demands, suits, judgments, proceedings, investigations or arbitrations) and reasonable expenses, including reasonable
accountant’s and reasonable attorney’s fees and expenses (together the “Losses”), incurred by such Stockholder Indemnitee before or after the date of this Agreement to the extent arising out of, resulting from, or relating
to (i) such Stockholder Indemnitee’s purchase and/or ownership of any Common Stock or (ii) any litigation to which any Stockholder Indemnitee is made a party in its capacity as a stockholder or owner of securities (or as a director,
officer, partner, member, manager, Affiliate or controlling person of any Lead Stockholder) of the Company (including any predecessor thereof); provided, that the foregoing indemnification rights in this Section 7(a)
shall not be available to the extent that (a) any such Losses are incurred as a result of such Stockholder Indemnitee’s willful misconduct or gross negligence; (b) any such Losses are incurred as a result of non-compliance by such Stockholder Indemnitee with any laws or regulations applicable to it; or (c) subject to the rights of contribution provided for below, to the extent indemnification for any Losses would
violate any applicable law or public policy. For purposes of this Section 7(a), none of the circumstances described in the limitations contained in the proviso in the immediately preceding sentence shall be deemed to apply
absent a final non-appealable judgment of a court of competent jurisdiction to such effect, in which case to the extent any such limitation is so determined to apply to any Stockholder Indemnitee as to any
previously advanced indemnity payments made by the Company under this Section 7(a), then such payments shall be promptly repaid by such Stockholder Indemnitee to the Company. The rights of any Stockholder Indemnitee to
indemnification hereunder will be in addition to any other rights any such party may have under any other agreement or instrument to which such Stockholder Indemnitee is or becomes a party or is or otherwise becomes a beneficiary or under law or
regulation. In the event of any payment of indemnification pursuant to this Section 7(a), to the extent that any Stockholder Indemnitee is indemnified for Losses, except as set forth in
Section 7(d), the Company will be subrogated to the extent of such payment to all of the related rights of recovery of the Stockholder Indemnitee to which such payment is made against all other Persons. Such Stockholder
Indemnitee shall execute all papers reasonably required to evidence such rights. The Company will be entitled at its election to participate in the defense of any third party claim upon which indemnification is due pursuant to this
Section 7(a) or to assume the defense thereof, with counsel reasonably satisfactory to such Stockholder Indemnitee unless, in the reasonable judgment of the Stockholder Indemnitee, a conflict of interest between the Company
and such Stockholder Indemnitee may exist, in which case such Stockholder Indemnitee shall have the right to assume its own defense and the Company shall be liable for all reasonable expenses therefor. Except as set forth above, should the Company
assume such defense all further defense costs of the Stockholder Indemnitee in respect of such third party claim shall be for the sole account of such party and not subject to indemnification hereunder. The Company will not without the prior written
consent of the Stockholder Indemnitee (which consent shall not be unreasonably withheld) effect any settlement of any threatened or pending third party claim in which such Stockholder Indemnitee is or could have been a party and be entitled to
indemnification hereunder unless such settlement solely involves the payment of money by the Company and includes an unconditional 

  
 7 

 
release of such Stockholder Indemnitee from all liability and claims that are the subject matter of such claim. If the indemnification provided for above is unavailable in respect of any Losses,
then the Company, in lieu of indemnifying an Stockholder Indemnitee, shall, if and to the extent permitted by law, contribute to the amount paid or payable by such Stockholder Indemnitee in such proportion as is appropriate to reflect the relative
fault of the Company and such Stockholder Indemnitee in connection with the actions which resulted in such Losses, as well as any other equitable considerations. 

(b)    The Company agrees to pay or reimburse (i) the Lead Stockholders for all reasonable costs and expenses
(including reasonable attorneys’ fees, charges, disbursement and expenses) incurred in connection with any amendment, supplement, modification or waiver of or to any of the terms or provisions of this Agreement or any related agreements and
(ii) each Lead Stockholder for all costs and expenses of such Lead Stockholder (including reasonable attorneys’ fees, charges, disbursement and expenses) incurred in connection with (1) the consent to any departure by the Company or
any of its Subsidiaries from the terms of any provision of this Agreement or any related agreements and (2) the enforcement or exercise by such Lead Stockholder of any right granted to it or provided for hereunder. 

(c)    The Company and its Subsidiaries shall obtain customary director and officer indemnity insurance on commercially
reasonable terms which insurance shall cover each member of the Board and the members of each board of directors of each of the Company’s Subsidiaries. The Company and its Subsidiaries shall enter into director indemnification agreements
substantially in the form attached as Exhibit A hereto, with each of the Nominees. 

(d)    The Company hereby acknowledges that the Stockholder Indemnitee may have certain rights to advancement
and/or indemnification by certain Affiliates of the GA Stockholder or certain Affiliates of the Warburg Stockholder (collectively, the “Fund Indemnitors”). In all events, (i) the Company hereby agrees that it
is the indemnitor of first resort (i.e., its obligation to a Stockholder Indemnitee to provide advancement and/or indemnification to such Stockholder Indemnitee are primary and any obligation of the
Fund Indemnitors (including any Affiliate thereof other than the Company) to provide advancement or indemnification hereunder or under any other indemnification agreement (whether pursuant to contract,
by-laws or charter), or any obligation of any insurer of the Fund Indemnitors to provide insurance coverage, for the same expenses, liabilities, judgments, penalties, fines and amounts paid in settlement
(including all interest, assessments and other charges paid or payable in connection with or in respect of such expenses, liabilities, judgments, penalties, fines and amounts paid in settlement) incurred by such Stockholder Indemnitee are secondary
and it irrevocably waives any claims against the Fund Indemnitors for contribution, subrogation, reimbursement or any other recovery of any kind for which the Company is liable pursuant to this Agreement and the Company’s by-laws or charter and (ii) if any Fund Indemnitor (or any Affiliate thereof, other than the Company) pays or causes to be paid, for any reason, any amounts otherwise indemnifiable hereunder or under any
other indemnification agreement (whether pursuant to contract, by-laws or charter) with such Stockholder Indemnitee, then (x) such Fund Indemnitor (or such Affiliate, as the case may be) shall be fully
subrogated to all rights of such Stockholder Indemnitee with respect to such payment and (y) the Company shall fully indemnify, reimburse and hold harmless such Fund Indemnitor (or such other Affiliate, as the case may be) for all
such payments actually made by such Fund Indemnitor (or such other Affiliate, as the case may be). 

  
 8 

 8.     Amendment and Waiver. Any provision of this Agreement may be amended or
waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by the Company and each Lead Stockholder that Beneficially Owns at least 5% of the Common Stock then outstanding, or in the case of a waiver,
by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. The Lead Stockholders shall not be obligated to
nominate all (or any) of the Nominees they are entitled to nominate pursuant to this Agreement for any election of Directors but the failure to do so shall not constitute a waiver of rights hereunder with respect to future elections;
provided, however, that in the event a Lead Stockholder fails to nominate all (or any) of the Nominees it is entitled to nominate pursuant to this Agreement prior to the mailing to stockholders of the Director Election Proxy Statement
relating to such election (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission), the Nominating, Corporate Governance and Compliance Committee of the Board shall be entitled
to nominate individuals in lieu of such Nominees for inclusion in the Board’s Slate and the applicable Director Election Proxy Statement with respect to the election for which such failure occurred and such Lead Stockholder shall be deemed to
have waived its rights hereunder with respect to such election; provided, further, however, that any such waiver shall only be effective if the Company has provided written notice to such Lead Stockholder of such Director
Election Proxy Statement no less than 20 business days, and no more than 40 business days, prior to the earlier of the mailing or filing date of such Director Election Proxy Statement. The rights and remedies herein provided shall be cumulative and
not exclusive of any rights or remedies provided by law. 
 9.    Benefit of Parties. This Agreement shall be binding upon and
shall inure to the benefit of the parties hereto and their respective permitted successors and assigns. Notwithstanding the foregoing, the Company may not assign any of its rights or obligations hereunder without the prior written consent of each
Lead Stockholder that Beneficially Own shares of Common Stock representing at least 5% of the Common Stock then outstanding. Except as otherwise expressly provided in Section 10, nothing herein contained shall confer or is
intended to confer on any third party or entity that is not a party to this Agreement any rights under this Agreement. 

10.    Assignment. Upon written notice to the Company, each Lead Stockholder may assign to any Affiliate (other than a portfolio
company) all of its rights hereunder and, following such assignment, such assignee shall be deemed to be a “Lead Stockholder” for all purposes hereunder. 

11.    Headings. Headings are for ease of reference only and shall not form a part of this Agreement. 

12.    Governing Law. This Agreement shall be construed in accordance with and governed by the law of the State of Delaware without
giving effect to the principles of conflicts of laws thereof. 
 13.    Jurisdiction. Any suit, action or proceeding seeking to
enforce any provision of, or based on any matter arising out of or in connection with, this Agreement may be brought against any of the parties in any federal court located in the State of Delaware or any Delaware state court, and each of the
parties hereby consents to the exclusive jurisdiction of such court (and of the 

  
 9 

 
appropriate appellate courts) in any such suit, action or proceeding and waives any objection to venue laid therein. Process in any such suit, action or proceeding may be served on any party
anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each of the parties agrees that service of process upon such party at the address referred to in
Section 20, together with written notice of such service to such party, shall be deemed effective service of process upon such party. 

14.    WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT. 
 15.    Entire Agreement. This Agreement constitutes the entire
agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, both written and oral among the parties with respect to the subject matter hereof. 

16.    Termination. This Agreement shall terminate upon the earliest to occur of any one of the following events: (a) (i) with
respect to the GA Stockholder only, at such time as the GA Stockholder no longer Beneficially Owns shares of Common Stock representing at least 5% of the Common Stock then outstanding and (ii) with respect to the Warburg Stockholder only, at
such time as the Warburg Stockholder no longer Beneficially Owns shares of Common Stock representing at least 5% of the Common Stock then outstanding and (b) the unanimous written consent of the parties hereto. Notwithstanding the foregoing,
Sections 7 through 23 shall survive any termination of this Agreement. 
 17.    Severability. If any provision of
this Agreement or the application thereof to any person or circumstance shall be invalid or unenforceable to any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not be affected
thereby and shall be enforced to the greatest extent permitted by law. 
 18.    Further Assurances. Each of the parties hereto
shall execute and deliver such further instruments and do such further acts and things as may be required to carry out the intent and purpose of this Agreement. 

19.    Specific Performance. Each of the parties hereto agree that irreparable damage would occur if any provision of this
Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions
hereof in any federal or state court located in the State of Delaware, in addition to any other remedy to which they are entitled at law or in equity. 

20.    Notices. All notices, requests and other communications to any party shall be in writing (including email or similar
writing) and shall be given: 
 If to the Company: 

Alignment Healthcare, Inc. 
 c/o
Alignment Healthcare USA, LLC 
 1100 West Town and Country Road, #1600 

  
 10 

 Orange, CA 92868 

Attention: General Counsel 
 Fax:
(949) 679-0005 
 Email: 

With a copy to (which shall not constitute notice): 

Paul, Weiss, Rifkind, Wharton & Garrison LLP 

1285 Avenue of the Americas 
 New
York, NY 10019-6064 
 Attention: Neil Goldman 

Email: ngoldman@paulweiss.com 

If to the GA Stockholder or any of its Nominees: 

c/o General Atlantic Service Company, L.P. 

55 East 52nd Street, 33rd Floor 

New York, NY 10055 
 Attention:

 Email: 
 With a copy to
(which shall not constitute notice): 
 Paul, Weiss, Rifkind, Wharton & Garrison LLP 

1285 Avenue of the Americas 
 New
York, NY 10019-6064 
 Attention: Neil Goldman 

Email: ngoldman@paulweiss.com 

If to the Warburg Stockholder or any of its Nominees: 

Warburg Pincus LLC 
 450
Lexington Avenue 
 New York, NY 10017 

Attention: 
 Email: 

or to such other address or email address as such party may hereafter specify for the purpose by notice to the other parties. Each such notice, request or
other communication shall be effective when delivered at the address specified in this Section 20 during regular business hours. 

21.    Enforcement. Each of the parties hereto covenants and agrees that the disinterested members of the Board have the right to
enforce, waive or take any other action with respect to this Agreement on behalf of the Company. 

  
 11 

 22.    Interpretation. Each of the parties hereto acknowledges that each party
has been represented by legal counsel in connection with this Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application
and is expressly waived. 
 23.    Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts, each
of which shall be deemed an original. This Agreement shall become effective when each party shall have received a counterpart hereof signed by each of the other parties. An executed copy or counterpart hereof delivered by facsimile shall be deemed
an original instrument. 
 [signature page follows] 

  
 12 

 IN WITNESS WHEREOF, the parties hereto have executed this Stockholders Agreement as of the
date first set forth above. 
  

			
	ALIGNMENT HEALTHCARE, INC.
		
	By:	 	 /s/ Thomas Freeman

		 	Name: Thomas Freeman
		 	Title:   CFO

  
 [Signature Page to
Stockholders Agreement] 

 
			
	GENERAL ATLANTIC (ALN HLTH), LP
	
	 By: General Atlantic (SPV) GP, LLC

Its: General Partner
  

By: General Atlantic LLC
 Its: Sole Member

		
	By:	 	 /s/ J. Frank Brown

		 	Name: J. Frank Brown
		 	Title:   Managing Director

  
 [Signature Page to
Stockholders Agreement] 

 
			
	WARBURG PINCUS PRIVATE EQUITY XII, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
		
	By:	 	WP Global LLC, its general partner
		
	By:	 	Warburg Pincus Partners II, L.P., its managing member
		
	By:	 	Warburg Pincus Partners GP LLC, its general partner
		
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director
	
	WP XII PARTNERS, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
		
	By:	 	WP Global LLC, its general partner
		
	By:	 	Warburg Pincus Partners II, L.P., its managing member
		
	By:	 	Warburg Pincus Partners GP LLC, its general partner
		
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director

  
 [Signature Page to
Stockholders Agreement] 

 
			
	WARBURG PINCUS PRIVATE EQUITY XII-B, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
	By:	 	WP Global LLC, its general partner
	By:	 	Warburg Pincus Partners II, L.P., its managing member
	By:	 	Warburg Pincus Partners GP LLC, its general partner
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director
	
	WARBURG PINCUS XII PARTNERS, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
	By:	 	WP Global LLC, its general partner
	By:	 	Warburg Pincus Partners II, L.P., its managing member
	By:	 	Warburg Pincus Partners GP LLC, its general partner
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director

  
 [Signature Page to
Stockholders Agreement] 

 
			
	WARBURG PINCUS PRIVATE EQUITY XII-D, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
	By:	 	WP Global LLC, its general partner
	By:	 	Warburg Pincus Partners II, L.P., its managing member
	By:	 	Warburg Pincus Partners GP LLC, its general partner
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director
	
	WARBURG PINCUS PRIVATE EQUITY XII-E, L.P.
		
	By:	 	Warburg Pincus XII, L.P., its general partner
	By:	 	WP Global LLC, its general partner
	By:	 	Warburg Pincus Partners II, L.P., its managing member
	By:	 	Warburg Pincus Partners GP LLC, its general partner
	By:	 	Warburg Pincus & Co., its managing member
		
	By:	 	 /s/ Thomas J. Carella

		 	Name: Thomas J. Carella
		 	Title:   Managing Director

  
 [Signature Page to
Stockholders Agreement]abcl-ex43_464.htm

Exhibit 4.3

DESCRIPTION OF SECURITIES

As of December 31, 2020, AbCellera Biologics, Inc. (the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Shares.

Description of Common Shares

The following description of our Common Shares is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended Articles (“Articles”) which was incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, and by applicable law. We encourage you to read our Articles and applicable provisions of the Business Corporations Act of British Columbia (the “BCBCA”) for additional information.

Authorized Share Capital

Our authorized share capital consists of an unlimited number of common shares, no par value (“Common Shares”), and an unlimited number of preferred shares, no par value (the “Preferred Shares”), issuable in series, all of which Preferred Shares are undesignated.

Common Shares

The holders of our Common Shares are entitled to one vote for each share held on all matters submitted to a vote of the shareholders. Holders of our Common Shares are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding Preferred Shares. Under the terms of our contribution agreements with Western Economic Diversification Canada, we are restricted from paying any dividends until we have repaid the contributions thereunder in full. Our Common Shares have no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

In the event of our liquidation, dissolution or winding up, holders of our Common Shares will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding Preferred Shares.

Our Common Shares are listed on the Nasdaq Global Select Market under the trading symbol “ABCL.”

The transfer agent and registrar for our Common Shares is Philadelphia Stock Transfer, Inc., located at 2320 Haverford Road, Suite 230, Ardmore, Pennsylvania 19003; telephone (484) 416-3124.

Preferred Shares

Our board of directors has the authority, without further action by our shareholders, to issue an unlimited number of Preferred Shares in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Common Shares. The issuance of our Preferred Shares could adversely affect the voting power of holders of Common Shares and the likelihood that such holders will receive dividend payments and payments upon our liquidation, dissolution or winding up. In addition, the issuance of Preferred Shares could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No Preferred Shares are currently outstanding, and we have no present plan to issue any Preferred Shares.

Registration Rights

The holders of 85,227,408 Common Shares, are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of an amended and restated investors’ rights agreement between us and holders of our preferred shares and are subject to the provisions of the lock-up agreements entered into by such holders of our preferred shares. The amended and restated investors’ rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including the estimated underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.

Demand Registration Rights

Beginning June 8, 2021, the holders of 85,227,408 Common Shares are entitled to demand registration rights. Under the terms of the amended and restated investors’ rights agreement, we will be required, upon the written request of holders of at least a majority of the securities eligible for registration then outstanding, to use all reasonable efforts to effect the registration of these registrable securities for public resale so long as the aggregate offering price, net of related fees and expenses, would be at least $15 million. We are required to effect only two registrations pursuant to this provision of the amended and restated investors’ rights agreement.

Form S-3 Registration Rights

Pursuant to the amended and restated investors’ rights agreement, if we are eligible to file a registration statement on Form S-3 or a Canadian short-form prospectus, upon the written request of shareholders holding at least 30% of the Common Shares issued upon the conversion of our prior preferred shares during the closing of our initial public offering (“IPO”) then outstanding we will be required to file a Form S-3 registration restatement or a Canadian short-form prospectus, with respect to outstanding securities of such shareholders having an anticipated aggregate offering, net of related fees and expenses, of at least $5.0 million. We are required to effect only two registrations in any 12-month period pursuant to this provision of the amended and restated investors’ rights agreement. The right to have such shares registered on 

Form S-3 or a Canadian short-form prospectus is further subject to other specified conditions and limitations.

Piggyback Registration Rights

Pursuant to the amended and restated investors’ rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of our Common Shares issuable upon the conversion of our preferred shares are entitled to include their shares in the registration. Subject to certain exceptions and limitations contained in the amended and restated investors’ rights agreement, we and the underwriters may limit the number of shares included in an underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.

Indemnification

Our amended and restated investors’ rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.

Expiration of Registration Rights

The demand registration rights, short form registration rights, and piggyback registration rights granted under the amended and restated investors’ rights agreement will terminate on the earlier of a fourth anniversary of the closing of our IPO, the closing of a deemed liquidation event, at such time when the holders’ shares may be sold without restriction pursuant to Rule 144 within a three-month period, or in such case that the sale of all such holder’s shares would not be a distribution under Section 2.5 or Section 2.6 of National Instrument 45-102, and would not be a control distribution (as defined in National Instrument 45-102).

Anti-Takeover Effects under the Business Corporations Act of British Columbia (BCBCA) and Provisions of Our Articles

Our Articles include a number of provisions that may have the effect of delaying, deferring or discouraging another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors (the “ Board”) rather than pursue non-negotiated takeover attempts. These provisions include the items described below:

•Classified or “Staggered” Board of Directors. With a staggered Board, only one-third of the members of the Board shall be elected at an annual meeting of shareholders, and a person can gain control of the Board only by successfully engaging in a proxy contest at two or more annual meetings.

•Number of Directors and Vacancies on the Board. The BCBCA provides that vacancies on the Board may be filled in two ways: (1) If the director was removed, the position can be filled by the shareholders at the shareholder meeting where the director is 

removed; (2) if there is a casual vacancy, such vacancy can be filled by the remaining directors. The Articles contain provisions establishing the right of the Board to fill a vacancy.

•Only those matters set forth in the notice of shareholder meetings may be approved at such meetings. The conduct of shareholder meetings are determined by the notice of meeting and avoids unexpected matters to be raised at meetings of shareholders.

•Advance Notice of Shareholders Proposals and Director Nominations. Shareholder proposals must be received well in advance of meetings at which such proposals are to be considered. Under the BCBCA, a person submitting a proposal must have been the registered or beneficial owner of one or more voting shares for an uninterrupted period of at least two years before the date of the signing of the proposal. In addition, the proposal must be signed by shareholders who, together with the submitter, are registered or beneficial owners of (i) at least 1% of the company’s voting shares, or (ii) shares with a fair market value exceeding an amount prescribed by regulation. The Articles contain advance notice provisions respecting the nomination of directors.

•Supermajority thresholds for amendment of certain provisions in the Articles. The BCBCA permits setting higher than simple majority thresholds for amendments to the articles. The Articles sets forth that certain provisions may not be amended without at least two thirds (2/3) of the votes cast in respect of such amendment being voted in the affirmative.

•Blank Check Preferred Stock. The Articles contain provisions allowing for “blank check” preferred shares and permit the Board to issue shares of preferred shares without the approval of shareholders.

•Prohibition on Shareholder Action by Written Consent. Under the BCBCA, shareholders are expressly authorized to act by written consent, but such written consent must be unanimous. 

•Exclusive Forum for Litigation Regarding Corporate and Securities Matters. The Articles contains a provision specifying that fundamental corporate matters be adjudicated in a court in British Columbia, and U.S. securities litigation be adjudicated in a U.S. federal court. 

Limitations on Liability and Indemnification Agreements

We are governed by the BCBCA. Under the BCBCA, and our articles, we may (or must, in the case of our Articles) indemnify all eligible parties against all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each director is deemed to have contracted with the Company on the terms of indemnity contained in our Articles.

For the purposes of such an indemnification:

“eligible party,” in relation to the Company, means an individual who

•is or was a director or officer of the Company;

•is or was a director or officer of another corporation

•at a time when the corporation is or was an affiliate of the Company, or

•at the request of the Company; or

	
 
	
•
	
at the request of the Company, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity and includes the heirs and personal or other legal representatives of that individual;

“eligible penalty” means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding;

“ eligible proceeding” means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company or an associated corporation:

•is or may be joined as a party, or

	
 
	
•
	
is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding;

“expenses” includes costs, charges and expenses, including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding; and

“proceeding” includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

In addition, under the BCBCA, the Company may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, provided that the Company first receives from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited by the restrictions noted below, the eligible party will repay the amounts advanced.

Notwithstanding the provisions of the Company’s Articles noted above, the Company must not indemnify an eligible party or pay the expenses of an eligible party, if any of the following circumstances apply:

	
 
	
•
	
if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses 

	
 
		
was made, the Company was prohibited from giving the indemnity or paying the expenses by its Articles;

	
 
	
•
	
if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Company is prohibited from giving the indemnity or paying the expenses by its Articles;

	
 
	
•
	
if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Company or the associated corporation, as the case may be; or

	
 
	
•
	
in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party’s conduct in respect of which the proceeding was brought was lawful.

In addition, if an eligible proceeding is brought against an eligible party by or on behalf of the Company or by or on behalf of an associated corporation, the Company must not do either of the following:

•indemnify the eligible party in respect of the proceeding; or

•pay the expenses of the eligible party in respect of the proceeding.

Notwithstanding any of the foregoing, and whether or not payment of expenses or indemnification has been sought, authorized or declined under the BCBCA or the Articles of the Company, on the application of the Company or an eligible party, the Supreme Court of British Columbia may do one or more of the following:

	
 
	
•
	
order the Company to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

	
 
	
•
	
order the Company to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

	
 
	
•
	
order the enforcement of, or any payment under, an agreement of indemnification entered into by the Company;

	
 
	
•
	
order the Company to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under this section; or

•make any other order the court considers appropriate.

The BCBCA and our Articles authorize us to purchase and maintain insurance for the benefit of an eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company, a current or former affiliate of the 

Company or a corporation, partnership, trust, joint venture or other unincorporated entity at the request of the Company.

In addition, we have entered, or will enter, into separate indemnity agreements with each of our directors and officers pursuant to which we agree to indemnify and hold harmless our directors and officers against any and all liability, loss, damage, cost or expense in accordance with the terms and conditions of the BCBCA and our Articles.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]